D
Emergent BioSolutions Inc.
EBS
$5.71
$0.203.63%
D
Sell
5/30/2024Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 5/30/2024 due to a major increase in the growth index, volatility index and total return index. EBIT increased 178.5% from -$50.7M to $39.8M, earnings per share increased from -$0.9538 to $0.17, and total revenue increased 8.6% from $276.6M to $300.4M.
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 5/30/2024 due to a major increase in the growth index, volatility index and total return index. EBIT increased 178.5% from -$50.7M to $39.8M, earnings per share increased from -$0.9538 to $0.17, and total revenue increased 8.6% from $276.6M to $300.4M.
E
Sell
12/7/2023Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 12/7/2023 due to a decline in the volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 12/7/2023 due to a decline in the volatility index.
D
Sell
11/21/2023Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 11/21/2023 due to an increase in the volatility index and solvency index.
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 11/21/2023 due to an increase in the volatility index and solvency index.
E
Sell
11/6/2023Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 11/6/2023 due to a decline in the volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 11/6/2023 due to a decline in the volatility index.
D
Sell
10/20/2023Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 10/20/2023 due to an increase in the volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 10/20/2023 due to an increase in the volatility index.
E
Sell
10/4/2023Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index and total return index.
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index and total return index.
D
Sell
9/15/2023Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 9/15/2023 due to an increase in the volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to D- from E+ on 9/15/2023 due to an increase in the volatility index.
E
Sell
8/30/2023Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 8/30/2023 due to a noticeable decline in the efficiency index, solvency index and volatility index. Net income declined 42.79% from -$183M to -$261.3M, and total capital declined 28.32% from $2.62B to $1.88B.
Emergent BioSolutions Inc. (EBS) was downgraded to E+ from D- on 8/30/2023 due to a noticeable decline in the efficiency index, solvency index and volatility index. Net income declined 42.79% from -$183M to -$261.3M, and total capital declined 28.32% from $2.62B to $1.88B.
D
Sell
6/21/2023Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D- from D on 6/21/2023 due to a decline in the volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to D- from D on 6/21/2023 due to a decline in the volatility index.
D
Sell
6/6/2023Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to D from D- on 6/6/2023 due to an increase in the volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to D from D- on 6/6/2023 due to an increase in the volatility index.
D
Sell
5/18/2023Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D- from D on 5/18/2023 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 298.28% from $92.8M to -$184M, EBIT declined 148.45% from -$58.2M to -$144.6M, and earnings per share declined from -$1.7635 to -$3.65.
Emergent BioSolutions Inc. (EBS) was downgraded to D- from D on 5/18/2023 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 298.28% from $92.8M to -$184M, EBIT declined 148.45% from -$58.2M to -$144.6M, and earnings per share declined from -$1.7635 to -$3.65.
D
Sell
11/10/2022Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D from D+ on 11/10/2022 due to a major decline in the valuation index, efficiency index and volatility index. Net income declined 34.22% from -$56.4M to -$75.7M.
Emergent BioSolutions Inc. (EBS) was downgraded to D from D+ on 11/10/2022 due to a major decline in the valuation index, efficiency index and volatility index. Net income declined 34.22% from -$56.4M to -$75.7M.
D
Sell
11/1/2022Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to D+ from D on 11/1/2022 due to an increase in the volatility index and valuation index.
Emergent BioSolutions Inc. (EBS) was upgraded to D+ from D on 11/1/2022 due to an increase in the volatility index and valuation index.
D
Sell
10/13/2022Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D from D+ on 10/13/2022 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.073 to -$1.13, EBIT declined 1,143.48% from $6.9M to -$72M, and the quick ratio declined from 2.48 to 1.94.
Emergent BioSolutions Inc. (EBS) was downgraded to D from D+ on 10/13/2022 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.073 to -$1.13, EBIT declined 1,143.48% from $6.9M to -$72M, and the quick ratio declined from 2.48 to 1.94.
D
Sell
4/18/2022Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D+ from C- on 4/18/2022 due to a decline in the volatility index and total return index.
Emergent BioSolutions Inc. (EBS) was downgraded to D+ from C- on 4/18/2022 due to a decline in the volatility index and total return index.
C
Hold
3/31/2022Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to C- from D+ on 3/31/2022 due to a significant increase in the growth index, efficiency index and volatility index. Operating cash flow increased 1,870.06% from $16.7M to $329M, EBIT increased 1,020.46% from -$34.7M to $319.4M, and net income increased 678.9% from -$32.7M to $189.3M.
Emergent BioSolutions Inc. (EBS) was upgraded to C- from D+ on 3/31/2022 due to a significant increase in the growth index, efficiency index and volatility index. Operating cash flow increased 1,870.06% from $16.7M to $329M, EBIT increased 1,020.46% from -$34.7M to $319.4M, and net income increased 678.9% from -$32.7M to $189.3M.
D
Sell
11/8/2021Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D+ from C on 11/8/2021 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0858 to -$0.61, EBIT declined 161.96% from $56M to -$34.7M, and total revenue declined 17.23% from $397.5M to $329M.
Emergent BioSolutions Inc. (EBS) was downgraded to D+ from C on 11/8/2021 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0858 to -$0.61, EBIT declined 161.96% from $56M to -$34.7M, and total revenue declined 17.23% from $397.5M to $329M.
C
Hold
5/28/2021Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to C from C+ on 5/28/2021 due to a major decline in the growth index, total return index and volatility index. Operating cash flow declined 97.92% from $245.1M to $5.1M, EBIT declined 63.09% from $258.5M to $95.4M, and earnings per share declined from $3.4228 to $1.28.
Emergent BioSolutions Inc. (EBS) was downgraded to C from C+ on 5/28/2021 due to a major decline in the growth index, total return index and volatility index. Operating cash flow declined 97.92% from $245.1M to $5.1M, EBIT declined 63.09% from $258.5M to $95.4M, and earnings per share declined from $3.4228 to $1.28.
C
Hold
4/22/2021Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to C+ from B- on 4/22/2021 due to a decline in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to C+ from B- on 4/22/2021 due to a decline in the total return index and volatility index.
B
Buy
4/7/2021Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B- from C+ on 4/7/2021 due to a large increase in the total return index, valuation index and volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to B- from C+ on 4/7/2021 due to a large increase in the total return index, valuation index and volatility index.
C
Hold
2/19/2021Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to C+ from C on 2/19/2021 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 369.37% from $39.5M to $185.4M, earnings per share increased from $0.73 to $3.4228, and EBIT increased 186.27% from $90.3M to $258.5M.
Emergent BioSolutions Inc. (EBS) was upgraded to C+ from C on 2/19/2021 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 369.37% from $39.5M to $185.4M, earnings per share increased from $0.73 to $3.4228, and EBIT increased 186.27% from $90.3M to $258.5M.
C
Hold
11/19/2020Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to C from C+ on 11/19/2020 due to a decline in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to C from C+ on 11/19/2020 due to a decline in the total return index and volatility index.
C
Hold
11/9/2020Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to C+ from B- on 11/9/2020 due to a major decline in the growth index, total return index and efficiency index. Earnings per share declined from $1.73 to $0.73, net income declined 57.39% from $92.7M to $39.5M, and EBIT declined 28.33% from $126M to $90.3M.
Emergent BioSolutions Inc. (EBS) was downgraded to C+ from B- on 11/9/2020 due to a major decline in the growth index, total return index and efficiency index. Earnings per share declined from $1.73 to $0.73, net income declined 57.39% from $92.7M to $39.5M, and EBIT declined 28.33% from $126M to $90.3M.
B
Buy
10/21/2020Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 10/21/2020 due to a decline in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 10/21/2020 due to a decline in the total return index and volatility index.
B
Buy
10/5/2020Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 10/5/2020 due to a large increase in the total return index.
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 10/5/2020 due to a large increase in the total return index.
B
Buy
9/18/2020Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 9/18/2020 due to a large decline in the total return index.
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 9/18/2020 due to a large decline in the total return index.
B
Buy
9/2/2020Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 9/2/2020 due to an increase in the valuation index and total return index.
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 9/2/2020 due to an increase in the valuation index and total return index.
B
Buy
8/17/2020Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 8/17/2020 due to a noticeable decline in the valuation index.
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 8/17/2020 due to a noticeable decline in the valuation index.
B
Buy
7/31/2020Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B from C on 7/31/2020 due to a significant increase in the total return index, growth index and valuation index. EBIT increased 1,186.21% from -$11.6M to $126M, earnings per share increased from -$0.2404 to $1.73, and operating cash flow increased 121.28% from $57.8M to $127.9M.
Emergent BioSolutions Inc. (EBS) was upgraded to B from C on 7/31/2020 due to a significant increase in the total return index, growth index and valuation index. EBIT increased 1,186.21% from -$11.6M to $126M, earnings per share increased from -$0.2404 to $1.73, and operating cash flow increased 121.28% from $57.8M to $127.9M.
C
Hold
2/27/2020Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to C from C- on 2/27/2020 due to a substantial increase in the growth index, valuation index and efficiency index. Operating cash flow increased 4,038.71% from -$3.1M to $122.1M, EBIT increased 61.95% from $70.7M to $114.5M, and total revenue increased 15.55% from $311.8M to $360.3M.
Emergent BioSolutions Inc. (EBS) was upgraded to C from C- on 2/27/2020 due to a substantial increase in the growth index, valuation index and efficiency index. Operating cash flow increased 4,038.71% from -$3.1M to $122.1M, EBIT increased 61.95% from $70.7M to $114.5M, and total revenue increased 15.55% from $311.8M to $360.3M.
C
Hold
10/24/2019Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to C- from D+ on 10/24/2019 due to an increase in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to C- from D+ on 10/24/2019 due to an increase in the total return index and volatility index.
D
Sell
8/2/2019Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to D+ from C- on 8/2/2019 due to a noticeable decline in the valuation index, total return index and efficiency index.
Emergent BioSolutions Inc. (EBS) was downgraded to D+ from C- on 8/2/2019 due to a noticeable decline in the valuation index, total return index and efficiency index.
C
Hold
5/15/2019Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to C- from C on 5/15/2019 due to a large decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.91 to 1.04.
Emergent BioSolutions Inc. (EBS) was downgraded to C- from C on 5/15/2019 due to a large decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.91 to 1.04.
C
Hold
2/25/2019Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to C from B- on 2/25/2019 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 195.28% from $173.97M to -$165.76M, earnings per share declined from $0.41 to -$0.0684, and net income declined 116.62% from $20.95M to -$3.48M.
Emergent BioSolutions Inc. (EBS) was downgraded to C from B- on 2/25/2019 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 195.28% from $173.97M to -$165.76M, earnings per share declined from $0.41 to -$0.0684, and net income declined 116.62% from $20.95M to -$3.48M.
B
Buy
12/21/2018Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 12/21/2018 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 68.12% from $67.48M to $21.51M, earnings per share declined from $0.98 to $0.41, and total revenue declined 21.14% from $220.2M to $173.65M.
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 12/21/2018 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 68.12% from $67.48M to $21.51M, earnings per share declined from $0.98 to $0.41, and total revenue declined 21.14% from $220.2M to $173.65M.
B
Buy
11/1/2018Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to B from B+ on 11/1/2018 due to a decline in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was downgraded to B from B+ on 11/1/2018 due to a decline in the total return index and volatility index.
B
Buy
10/11/2018Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B+ from B on 10/11/2018 due to a major increase in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to B+ from B on 10/11/2018 due to a major increase in the total return index and volatility index.
B
Buy
8/6/2018Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 8/6/2018 due to a significant increase in the growth index, valuation index and volatility index. Operating cash flow increased 3,589.61% from -$991 to $34.58M, earnings per share increased from -$0.1 to $0.98, and EBIT increased 894.21% from -$8.5M to $67.48M.
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 8/6/2018 due to a significant increase in the growth index, valuation index and volatility index. Operating cash flow increased 3,589.61% from -$991 to $34.58M, earnings per share increased from -$0.1 to $0.98, and EBIT increased 894.21% from -$8.5M to $67.48M.
B
Buy
5/8/2018Downgrade
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 5/8/2018 due to a major decline in the growth index, valuation index and total return index. EBIT declined 115.29% from $55.58M to -$8.5M, earnings per share declined from $0.67 to -$0.1, and operating cash flow declined 101.26% from $78.95M to -$991.
Emergent BioSolutions Inc. (EBS) was downgraded to B- from B on 5/8/2018 due to a major decline in the growth index, valuation index and total return index. EBIT declined 115.29% from $55.58M to -$8.5M, earnings per share declined from $0.67 to -$0.1, and operating cash flow declined 101.26% from $78.95M to -$991.
B
Buy
11/6/2017Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 11/6/2017 due to a major increase in the total return index, growth index and solvency index. Earnings per share increased from $0.1125 to $0.6826, EBIT increased 457.46% from $8.57M to $47.77M, and total revenue increased 48.29% from $100.77M to $149.43M.
Emergent BioSolutions Inc. (EBS) was upgraded to B from B- on 11/6/2017 due to a major increase in the total return index, growth index and solvency index. Earnings per share increased from $0.1125 to $0.6826, EBIT increased 457.46% from $8.57M to $47.77M, and total revenue increased 48.29% from $100.77M to $149.43M.
B
Buy
9/15/2017Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to B- from C+ on 9/15/2017 due to a noticeable increase in the total return index and volatility index.
Emergent BioSolutions Inc. (EBS) was upgraded to B- from C+ on 9/15/2017 due to a noticeable increase in the total return index and volatility index.
C
Hold
8/4/2017Upgraded
Emergent BioSolutions Inc. (EBS) was upgraded to C+ from C on 8/4/2017 due to an increase in the total return index, volatility index and efficiency index. Total capital increased 1.22% from $858.81M to $869.29M.
Emergent BioSolutions Inc. (EBS) was upgraded to C+ from C on 8/4/2017 due to an increase in the total return index, volatility index and efficiency index. Total capital increased 1.22% from $858.81M to $869.29M.
C
Hold
9/22/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to C from C+ on 9/22/2016 due to a noticeable decline in the volatility index, total return index and valuation index.
Emergent BioSolutions, Inc. (EBS) was downgraded to C from C+ on 9/22/2016 due to a noticeable decline in the volatility index, total return index and valuation index.
C
Hold
8/25/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to C+ from B- on 8/25/2016 due to a decline in the volatility index, total return index and solvency index.
Emergent BioSolutions, Inc. (EBS) was downgraded to C+ from B- on 8/25/2016 due to a decline in the volatility index, total return index and solvency index.
B
Buy
8/8/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B- from B on 8/8/2016 due to a significant decline in the total return index, valuation index and volatility index.
Emergent BioSolutions, Inc. (EBS) was downgraded to B- from B on 8/8/2016 due to a significant decline in the total return index, valuation index and volatility index.
B
Buy
6/24/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B from B+ on 6/24/2016 due to a decline in the total return index and volatility index.
Emergent BioSolutions, Inc. (EBS) was downgraded to B from B+ on 6/24/2016 due to a decline in the total return index and volatility index.
B
Buy
6/9/2016Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to B+ from B on 6/9/2016 due to a major increase in the growth index, total return index and valuation index. Operating cash flow increased 1,131.11% from $3.07M to $37.8M.
Emergent BioSolutions, Inc. (EBS) was upgraded to B+ from B on 6/9/2016 due to a major increase in the growth index, total return index and valuation index. Operating cash flow increased 1,131.11% from $3.07M to $37.8M.
B
Buy
4/8/2016Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to B from B- on 4/8/2016 due to a major increase in the total return index and volatility index.
Emergent BioSolutions, Inc. (EBS) was upgraded to B from B- on 4/8/2016 due to a major increase in the total return index and volatility index.
B
Buy
3/11/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B- from B+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
Emergent BioSolutions, Inc. (EBS) was downgraded to B- from B+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
B
Buy
3/4/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B+ from A- on 3/4/2016 due to a significant decline in the growth index and total return index. Operating cash flow declined 97.07% from $104.76M to $3.07M, and earnings per share declined from $0.794 to $0.7101.
Emergent BioSolutions, Inc. (EBS) was downgraded to B+ from A- on 3/4/2016 due to a significant decline in the growth index and total return index. Operating cash flow declined 97.07% from $104.76M to $3.07M, and earnings per share declined from $0.794 to $0.7101.
A
Buy
1/25/2016Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to A- from A on 1/25/2016 due to a decline in the total return index.
Emergent BioSolutions, Inc. (EBS) was downgraded to A- from A on 1/25/2016 due to a decline in the total return index.
A
Buy
1/8/2016Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to A from A- on 1/8/2016 due to a large increase in the total return index and volatility index.
Emergent BioSolutions, Inc. (EBS) was upgraded to A from A- on 1/8/2016 due to a large increase in the total return index and volatility index.
A
Buy
12/24/2015Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to A- from B+ on 12/24/2015 due to a noticeable increase in the total return index, solvency index and volatility index.
Emergent BioSolutions, Inc. (EBS) was upgraded to A- from B+ on 12/24/2015 due to a noticeable increase in the total return index, solvency index and volatility index.
B
Buy
11/10/2015Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to B+ from B on 11/10/2015 due to an increase in the valuation index, growth index and efficiency index. Operating cash flow increased 4,085.34% from $2.5M to $104.76M, EBIT increased 177.98% from $21.45M to $59.63M, and net income increased 162% from $14.1M to $36.94M.
Emergent BioSolutions, Inc. (EBS) was upgraded to B+ from B on 11/10/2015 due to an increase in the valuation index, growth index and efficiency index. Operating cash flow increased 4,085.34% from $2.5M to $104.76M, EBIT increased 177.98% from $21.45M to $59.63M, and net income increased 162% from $14.1M to $36.94M.
B
Buy
11/5/2015Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B from B+ on 11/5/2015 due to a decline in the total return index and valuation index.
Emergent BioSolutions, Inc. (EBS) was downgraded to B from B+ on 11/5/2015 due to a decline in the total return index and valuation index.
B
Buy
10/21/2015Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B+ from A- on 10/21/2015 due to a noticeable decline in the total return index, volatility index and valuation index.
Emergent BioSolutions, Inc. (EBS) was downgraded to B+ from A- on 10/21/2015 due to a noticeable decline in the total return index, volatility index and valuation index.
A
Buy
10/6/2015Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to A- from B+ on 10/6/2015 due to an increase in the valuation index.
Emergent BioSolutions, Inc. (EBS) was upgraded to A- from B+ on 10/6/2015 due to an increase in the valuation index.
B
Buy
9/14/2015Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to B+ from A- on 9/14/2015 due to a noticeable decline in the total return index.
Emergent BioSolutions, Inc. (EBS) was downgraded to B+ from A- on 9/14/2015 due to a noticeable decline in the total return index.
A
Buy
8/7/2015Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to A- from B on 8/7/2015 due to a major increase in the total return index, valuation index and growth index. Total revenue increased 98.19% from $63.63M to $126.11M.
Emergent BioSolutions, Inc. (EBS) was upgraded to A- from B on 8/7/2015 due to a major increase in the total return index, valuation index and growth index. Total revenue increased 98.19% from $63.63M to $126.11M.
B
Buy
3/6/2015Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to B from C+ on 3/6/2015 due to a significant increase in the volatility index, growth index and total return index. EBIT increased 53.88% from $31.03M to $47.75M, earnings per share increased from $0.493 to $0.7311, and total revenue increased 7.26% from $137.95M to $147.98M.
Emergent BioSolutions, Inc. (EBS) was upgraded to B from C+ on 3/6/2015 due to a significant increase in the volatility index, growth index and total return index. EBIT increased 53.88% from $31.03M to $47.75M, earnings per share increased from $0.493 to $0.7311, and total revenue increased 7.26% from $137.95M to $147.98M.
C
Hold
11/13/2014Upgraded
Emergent BioSolutions, Inc. (EBS) was upgraded to C+ from C on 11/13/2014 due to a major increase in the growth index, solvency index and efficiency index. Operating cash flow increased 629.49% from $10.82M to $78.92M, net income increased 334.12% from $5.03M to $21.83M, and EBIT increased 294.71% from $7.86M to $31.03M.
Emergent BioSolutions, Inc. (EBS) was upgraded to C+ from C on 11/13/2014 due to a major increase in the growth index, solvency index and efficiency index. Operating cash flow increased 629.49% from $10.82M to $78.92M, net income increased 334.12% from $5.03M to $21.83M, and EBIT increased 294.71% from $7.86M to $31.03M.
C
Hold
6/16/2014Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to C from C+ on 6/16/2014 due to a large decline in the volatility index and total return index.
Emergent BioSolutions, Inc. (EBS) was downgraded to C from C+ on 6/16/2014 due to a large decline in the volatility index and total return index.
C
Hold
5/16/2014Downgrade
Emergent BioSolutions, Inc. (EBS) was downgraded to C+ from B on 5/16/2014 due to a substantial decline in the valuation index, growth index and solvency index. Operating cash flow declined 438.44% from $8.64M to -$29.25M, debt to equity increased from 0.13 to 0.53, and earnings per share declined from $0.4049 to -$0.55.
Emergent BioSolutions, Inc. (EBS) was downgraded to C+ from B on 5/16/2014 due to a substantial decline in the valuation index, growth index and solvency index. Operating cash flow declined 438.44% from $8.64M to -$29.25M, debt to equity increased from 0.13 to 0.53, and earnings per share declined from $0.4049 to -$0.55.
NYSE
03/14/2025 4:00PM Eastern
Quotes delayed
